Retrospective study of the security about nucleoside analogues to chronic Hepatitis B virus infected women in late pregnancy
10.3760/cma.j.issn.1003-9279.2016.04.014
- VernacularTitle:慢性乙型肝炎病毒感染女性孕晚期应用核苷(酸)类似物安全性的回顾性研究
- Author:
Li LI
1
;
Wei YI
;
Yuhong HU
;
Min LIU
;
Gang WAN
Author Information
1. 首都医科大学附属北京地坛医院妇产科
- Keywords:
Hepatitis B virus;
Nucleosides;
Pregnancy;
Security
- From:
Chinese Journal of Experimental and Clinical Virology
2016;30(4):393-397
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the security of nucleoside analogues to pregnant women with chronic Hepatitis B virus (HBV) infection in late pregnancy.Methods Pregnant women with chronic HBV infection who delivered in the Beijing Ditan Hospital were retrospectively collected through the hospital information system (HIS).They were divided into two groups according to whether using nucleoside analogues after 28 weeks of gestation:treatment group (lamivudine,telbivudine or tenofovir used) and control group (no drug used).The incidence of pregnancy complications and neonatal adverse events were compared between the two groups.Results Total of 4 018 pregnant women met the requirements were collected,1 045 in treatment group,2 973 in control group.In treatment group,487 cases used lamivudine,556 cases used telbivudine and 2 cases used tenofovir.The cesarean delivery rate of the two groups are similar(49.5％ vs 51.7％ P =0.306).There is no significant difference in pregnancy complications including perinatal Increased bile acid,polyhydramnios,oligohydramnios,postpartum hemorrhage,premature delivery and Ⅲ degree amniotic fluid dung (P ＞ 0.05).And there is no significant difference in newborn birth weight(3390 g vs 3 389 g P =0.728),body length(50.22 cm vs 50.20 cm P =0.577),the first minute apgar score(9.96 vs 9.94 P =0.168) and the incidence of birth defects(1.5％ vs 1.4％ P =0.783) between the two groups.Furthermore,the differences of incidence of pregnancy complications and neonatal adverse events are compared between the lamivudine group and telbivudine group.It shows no significant difference.Conclusion Using nucleoside analogues in late pregnancy dose not increase the incidence of pregnancy complications and birth defects,dose not affect fetus development intrauterinely.They are generally secure to mother and fetus.The safety of lamivudine and telbivudine in late pregnancy is approximately the same.While,long-term,careful follow-up observations are still needed.
